Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
In utero hematopoietic stem cell transfer: current status and future strategies
Autore:
Surbek, DV; Gratwohl, A; Holzgreve, W;
Indirizzi:
Univ Basel Hosp, Dept Obstet & Gynecol, CH-4031 Basel, Switzerland Univ Basel Hosp Basel Switzerland CH-4031 ol, CH-4031 Basel, Switzerland Univ Basel, Div Hematol, Basel, Switzerland Univ Basel Basel Switzerland niv Basel, Div Hematol, Basel, Switzerland
Titolo Testata:
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY
fascicolo: 1, volume: 85, anno: 1999,
pagine: 109 - 115
SICI:
0301-2115(199907)85:1<109:IUHSCT>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; SEVERE COMBINED IMMUNODEFICIENCY; IN-UTERO; CORD-BLOOD; INUTERO TRANSPLANTATION; PROGENITOR CELLS; GENETIC-DISEASES; MATERNAL BLOOD; UMBILICAL-CORD; FETAL CELLS;
Keywords:
in utero transplantation; fetal therapy; hematopoietic stem cells;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Surbek, DV Univ Basel Hosp, Dept Obstet & Gynecol, Schanzenstr 46, CH-4031Basel, Switzerland Univ Basel Hosp Schanzenstr 46 Basel Switzerland CH-4031 rland
Citazione:
D.V. Surbek et al., "In utero hematopoietic stem cell transfer: current status and future strategies", EUR J OB GY, 85(1), 1999, pp. 109-115

Abstract

Successful prenatal treatment of severe immunodeficiencies by allogeneic hematopoietic stem cell transplantation in utero has been reported. Though other diseases like hemoglobinopathies or storage diseases are potentially amenable to this novel therapeutic approach, no success has yet been achieved in recipients without severe immunodeficiency. Graft rejection by the developing fetus and/or lack of selective, competitive advantage of donor versus host stem cells preventing stable engraftment seem to be the major obstacles. Several strategies to overcome these hurdles are being explored in preclinical settings, including timing and repeated dosing of stem cell administration to the fetus, ex vivo modification of the transplant, using different fetal compartments as targets for early stem cell transfer, or inducing microchimerism for postnatal transplantation from the same donor. Ln addition, the exact definition of the basic concept of early fetal immunologic naivete and the understanding of the molecular basics of migration and homing in fetal hematopoiesis system seem mandatory for a successful approach. Gene therapy using ex vivo transduced autologous cord blood cells or directgene targeting in utero are other potential means to correct hematopoieticand immunologic single gene disorders in utero, though this approach is still away from the stage of clinical trials. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 10:23:21